Technologies to Reduce Caregiver Burden for Informal Caregivers of People With Dementia (TECH@HOME)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02733939 |
Recruitment Status :
Completed
First Posted : April 12, 2016
Last Update Posted : August 14, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dementia | Device: Home monitoring kit | Not Applicable |
While the enormous technological progress made in recent years has put technologies, such as mobile devices and smart phones, in the reach of many, innovators in dementia care are just starting to explore the full potential of these developments to transform them into valuable products and services for users. There is indeed a lack of studies that evaluate the effectiveness and cost-effectiveness of these new technologically-enriched interventions targeted at people with dementia. Previous large scale evaluations of the impact of telemedicine and telecare, such as the Whole Demonstrator System in the United Kingdom, did not include people with dementia despite Alzheimer's disease being one of the most burdensome diseases in Europe.
This randomized controlled trial aims to evaluate the effects of new technologies on caregiver burden by reducing the time spent in supervision. The trial builds on previous promising results from the UP-TECH project in Italy (https://clinicaltrials.gov/ct2/show/NCT01700556) . The technologies used in TECH@HOME will include similar, but improved, home monitoring kits potentially leading to a greater impact on caregivers' caring conditions. In addition, while the UP-TECH study did not allow the researchers to estimate the impact of the technology as a "stand-alone" intervention (the monitoring kits were only given in combination with case-management support), TECH@HOME will overcome this limitation thanks to the possibility to compare a group of technology users vs. non-users. Results from this intervention in dementia care in Sweden hold the potential to inform regional and national policy makers in Sweden and beyond.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 90 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Åldrande: en Innovativ Och teknologistödd hemmiljö för äldre Patienter Med Alzheimers Sjukdom, TECH@HOME. |
Study Start Date : | March 2016 |
Actual Primary Completion Date : | May 2019 |
Actual Study Completion Date : | May 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Technology intervention
Patients randomized in the intervention group will receive a technical home monitoring kit for 12 months. The kits will be composed of a control unit and a set of sensors that immediately notify caregivers, through their phones, of any potential risks for the person with dementia. The kit will have home leaving sensors, bed occupancy sensors, smoke and water leak sensors, automatic lights, and other interactive functions. These devices will be connected to a single-board microcontroller that will transmit alarm messages to the caregivers in case of need.
|
Device: Home monitoring kit
The home monitoring kits notify the caregivers about potentially dangerous situations, such as when the person with dementia:
Depending on the personal choice of the study participants, the kit will also :
|
No Intervention: Usual care
Patients receiving usual care, as provided to people with dementia in Southern Sweden can vary. In the target area, people with dementia usually receive comparable pharmaceutical treatment depending on the dementia type, as prescribed by a general practitioner or a specialist at a memory clinic. The social worker from the Municipality ("Biståndshandläggaren") where the person resides, together with the district nurse, have a meaningful role in tailoring the care plan by mediating access to other care services such as respite care homes, home help and (dementia) nurse home visits. Use of such services depends on the specific needs of the person with dementia, which can also be unrelated to dementia, but rather dependent upon concomitant health and social issues.
|
- Change from baseline in time spent in informal care at month 3 [ Time Frame: 3 months ]The amount of informal care provided by caregivers to the persons with dementia, considered as a proxy of the caregiver burden, will be measured in hours/week and assessed using a specific section of the Resource Utilization in Dementia (RUD) instrument.
- Change from baseline in time spent in informal care at month 12 [ Time Frame: 12 months ]The amount of informal care provided by caregivers to the persons with dementia, considered as a proxy of the caregiver burden, will be measured in hours/week and assessed using a specific section of the Resource Utilization in Dementia (RUD) instrument.
- Change from baseline in Quality of Life of the person with dementia at month 3 [ Time Frame: 3 months ]Quality of life of the person with dementia will be measured using the QOL-AD instrument which has been developed in collaboration with caretakers, caregivers and experts in dementia care to ensure validity. Previous studies suggest that the instrument's validity and reliability are satisfactory in a study population of people with dementia.
- Change from baseline in Quality of Life of the person with dementia at month 12 [ Time Frame: 12 months ]Quality of life of the person with dementia will be measured using the QOL-AD instrument which has been developed in collaboration with caretakers, caregivers and experts in dementia care to ensure validity. Previous studies suggest that the instrument's validity and reliability are satisfactory in a study population of people with dementia.
- Change from baseline in Fear of falling at month 3 [ Time Frame: 3 months ]Fear of falling of the person with dementia will be measured using the 16-item Falls Efficacy Scale-International (FES-I). The evaluation of the Swedish version of the instrument showed high internal reliability also among people with cognitive impairment.
- Change from baseline in Fear of falling at month 12 [ Time Frame: 12 months ]Fear of falling of the person with dementia will be measured using the 16-item Falls Efficacy Scale-International (FES-I). The evaluation of the Swedish version of the instrument showed high internal reliability also among people with cognitive impairment.
- Change from baseline in Quality of life of the caregiver at month 3 [ Time Frame: 3 months ]Quality of life of the caregiver will be assessed using the EQ-5D-3L. This standardized instrument to measure health outcomes has been used and validated in previous Swedish studies.
- Change from baseline in Quality of life of the caregiver at month 12 [ Time Frame: 12 months ]Quality of life of the caregiver will be assessed using the EQ-5D-3L. This standardized instrument to measure health outcomes has been used and validated in previous Swedish studies.
- Change from baseline in Caregiver anxiety at month 3 [ Time Frame: 3 months ]Caregiver anxiety will be assessed using the anxiety component of the Hospital Anxiety and Depression Scale (HADS). HADS is a 14-item scale; seven of the items relate to anxiety and seven relate to depression; each item is a Likert scale rated from 0 to 3, and this means that the overall score for either anxiety or depression will be range from 0 to 21.
- Change from baseline in Caregiver anxiety at month 12 [ Time Frame: 12 months ]Caregiver anxiety will be assessed using the anxiety component of the Hospital Anxiety and Depression Scale (HADS). HADS is a 14-item scale; seven of the items relate to anxiety and seven relate to depression; each item is a Likert scale rated from 0 to 3, and this means that the overall score for either anxiety or depression will be range from 0 to 21.
- Change from baseline in Caregiver burden using the Zarit Burden Inventory (ZBI) at month 3 [ Time Frame: 3 months ]The Zarit Burden Inventory (ZBI) will be used to measure the level of caregiver burden. This is the instrument most consistently used in dementia caregiving research, and it is often used to measure the change of caregiver burden over time, resulting from the progression of the disease severity of the care recipient or from interventions aimed at reducing burden. The revised version of the Zarit with 22 items will be used.
- Change from baseline in Caregiver burden using the Zarit Burden Inventory (ZBI) at month 12 [ Time Frame: 12 months ]The Zarit Burden Inventory (ZBI) will be used to measure the level of caregiver burden. This is the instrument most consistently used in dementia caregiving research, and it is often used to measure the change of caregiver burden over time, resulting from the progression of the disease severity of the care recipient or from interventions aimed at reducing burden. The revised version of the Zarit with 22 items will be used.
- Domestic accidents at month 3 [ Time Frame: 3 months ]This outcome is measured as the total count of domestic accidents, defined as: 1) accidental falls, 2) cuts, 3) episodes of wandering outside the home, 4) burns and fires in the home, 5) flooding which will be assessed using an ad-hoc form.
- Domestic accidents at month 12 [ Time Frame: 12 months ]This outcome is measured as the total count of domestic accidents, defined as: 1) accidental falls, 2) cuts, 3) episodes of wandering outside the home, 4) burns and fires in the home, 5) flooding which will be assessed using an ad-hoc form.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria for the person with dementia:
- a diagnose of major neurocognitive disorders with mild to moderate severity (DSM-5) (following the new diagnostic criteria of the American Psychiatric Association;
- A score between 10 and 24 on the Mini-Mental State Examination (MMSE-SR);
- A score between 1 and 5 in the Global Deterioration Scale (GDS)
- Community dwelling;
- Able to speak and understand Swedish;
- Have at least one informal caregiver.
Exclusion Criteria for the person with dementia:
- Lack of informed consent;
- Being fully dependent on caregiver support for the Activities of Daily Living;
- Presence of severe diseases associated with a life expectancy of less than 6 months;
- Intention of moving to institutionalized care during the study period;
- Unwillingness to use technological devices for home assistance and safety;
- Being enrolled in another ongoing trial;
- Substance use disorder (DSM-5).
Specific inclusion criteria for the informal caregiver are:
- Lack of informed consent;
- Unwillingness to use technological devices for home assistance and safety;
- Presence of severe diseases associated with a life expectancy of less than 6 months;
- Being already enrolled in another ongoing trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02733939
Sweden | |
Memory Clinic, Hospital of Ängelholm | |
Ängelholm, Skåne, Sweden |
Principal Investigator: | Carlos Chiatti, PhD | Lund University and Italian National Institute on Health and Ageing (INRCA) |
Responsible Party: | Lund University |
ClinicalTrials.gov Identifier: | NCT02733939 |
Other Study ID Numbers: |
2014-4913 |
First Posted: | April 12, 2016 Key Record Dates |
Last Update Posted: | August 14, 2019 |
Last Verified: | August 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
technology informal care caregiver burden |
Dementia Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Neurocognitive Disorders Mental Disorders |